Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Institut de Recherches Internationales Servier
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier (France)
MAJ Il y a 4 ans
Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack
Not provided at time of registration and not expected to be available in the future
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier
MAJ Il y a 4 ans
Pharmacokinetics and safety of agomelatine in children (from 7 to less than 12 years) and adolescents (from 12 to less than 18 years) with Depressive or Anxiety Disorder
The primary objective is to evaluate pharmacokinetics of 3 doses of agomelatine in patients from 7 to less than 18 years suffering from Depressive or Anxiety Disorder.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier
MAJ Il y a 4 ans
Evaluation of efficacy and clinical benefit of agomelatine (25 to 50 mg/day) over a 6-month treatment period in patients with Major Depressive Disorder.A randomised, double-blind, international multicentre study with parallel groups versus duloxetine (60 mg/day).Twenty-four weeks of treatment
Long-term antidepressant efficacy of agomelatine compared to duloxetine.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier
MAJ Il y a 4 ans
Efficacy and safety of agomelatine (25mg/day with blinded potential adjustment to 50mg/day) versus escitalopram (10mg/day with blinded potential adjustment to 20mg/day) given orally for 12 weeks in non-depressed out-patients with severe Generalized Anxiety Disorder
To assess the efficacy of agomelatine compared to escitalopram after a 12-week treatment in non-depressed out-patients suffering from severe Generalized Anxiety Disorder (GAD).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier (France)
MAJ Il y a 4 ans
Phase I study of oral administration of S 78454 in association with doxorubicin in patients with solid tumour
Not provided at time of registration and not expected to be available in the future
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier (France)
MAJ Il y a 4 ans
Long-term efficacy and safety of agomelatine in non-depressed out-patients with generalized anxiety disorder. A 26-week randomised double-blind placebo-controlled parallel group study following an open-label period of 16 weeks with agomelatine (25 mg/day with the possibility for blinded dose-adjustment to 50 mg/day)
Not provided at time of registration and not expected to be available in the future
Pays
Canada
,
Denmark
,
Estonia
,
Finland
,
Hungary
,
Sweden
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier (France)
MAJ Il y a 4 ans
S 05985 combination versus AT1-Receptor Blocker/thiazide: a comparison of blood pressure lowering - efficacy and safety
Not provided at time of registration and not expected to be available in the future
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier (France)
MAJ Il y a 4 ans
Early effect of agomelatine on general interest in outpatients suffering major depressive disorder
Not provided at time of registration and not expected to be available in the future
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier
MAJ Il y a 4 ans
Efficacy and safety of agomelatine for 12 weeks in non-depressed out-patients with Generalised Anxiety Disorder
To confirm the superiority of agomelatine compared to placebo on anxiety in non-depressed out-patients suffering from GAD
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Institut de Recherches Internationales Servier (France)
MAJ Il y a 4 ans
The efficacy and safety of strontium ranelate versus placebo in the treatment of knee osteoarthritis
Not provided at time of registration and not expected to be available in the future
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
2
3
4
5
6
7
8
9
10
11
Suivant